These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38232909)

  • 21. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
    Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
    BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equity, expense, and expertise in biologic commissioning: adding the patient to the equation.
    Tucknott S; McAteer H
    Expert Opin Biol Ther; 2024 Mar; 24(3):147-155. PubMed ID: 38509688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
    Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
    Lee A; Scott LJ
    BioDrugs; 2020 Apr; 34(2):235-244. PubMed ID: 32207094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare.
    Allen KD; Kiefer MK; Butnariu M; Afzali A
    Arch Gynecol Obstet; 2022 Dec; 306(6):1929-1937. PubMed ID: 35249153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities.
    Kaneko S; Tsuruta N; Yamaguchi K; Miyagi T; Takahashi K; Higashi Y; Morizane S; Nomura H; Yamaguchi M; Hino R; Sawada Y; Nakamura M; Ohyama B; Ohata C; Yonekura K; Hayashi H; Yanase T; Matsuzaka Y; Sugita K; Kikuchi S; Mitoma C; Nakahara T; Furue M; Okazaki F; Koike Y; Imafuku S;
    J Dermatol; 2020 Feb; 47(2):128-132. PubMed ID: 31763718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study.
    Colombo D; Frassi M; Pagano Mariano G; Fusaro E; Lomater C; Del Medico P; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Grassi W; Grembiale RD; Guggino G; Mazzone A; Tirri E; Perricone R; Sarzi Puttini PC; De Vita S; Conti F; Ori A; Simoni L; Fiocchi M; Orsenigo R; Zagni E;
    BMC Rheumatol; 2022 Sep; 6(1):57. PubMed ID: 36089612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
    Atia O; Pujol-Muncunill G; Navas-López VM; Orlanski-Meyer E; Ledder O; Lev-Tzion R; Focht G; Shteyer E; Stein R; Aloi M; Russell RK; Martin-de-Carpi J; Turner D
    Aliment Pharmacol Ther; 2022 Sep; 56(5):794-801. PubMed ID: 35735987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry.
    Doolan BJ; Koye D; Ling J; Cains GD; Baker C; Foley P; Dolianitis C
    Australas J Dermatol; 2021 Feb; 62(1):e47-e54. PubMed ID: 32885846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study.
    Sticherling M; McPherson T; de Lucas Laguna R; Costanzo A; Reed C; Artime E; Robert C; Lucas J; Schuster C; Mahé E
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1793-1808. PubMed ID: 35797001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use.
    Kimura Y; Suzukawa M; Inoue N; Imai S; Akazawa M; Matsui H
    World Allergy Organ J; 2021 Nov; 14(11):100600. PubMed ID: 34820049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study.
    Chen CB; Huang YT; Hsiao CC; Chang SH; Chi CC
    BioDrugs; 2022 Sep; 36(5):657-666. PubMed ID: 35994233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.